Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

THE TRUTH ABOUT: 3 | History Defined

Surrozen Commences Phase 1 Study of SZN-1326 In Ulcerative Colitis

Surrozen, Inc. (NASDAQ: SRZN) announced that the first patient has been dosed in the Phase 1 clinical trial to evaluate its drug candidate SZN-1326 for the potential treatment of moderate to severe ulcerative colitis.

New treatment available on NHS to ulcerative colitis sufferers in Scotland

New treatment available on NHS to ulcerative colitis sufferers in Scotland

The Scottish Medicines Consortium has approved the new tablet called filgotinib.

The Independent UK

The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints

The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints

Here's a roundup of top developments in the biotech space over the last 24 hours.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Connect Biopharma Stock Plunges As Ulcerative Colitis Candidate Flunks In Mid-Stage Study

Connect Biopharma Holdings Limited (NASDAQ:CNTB) announced topline results at 12 weeks from its Phase 2 trial for CBP-307 (CBP-307CN002) for ulcerative colitis. CBP-307 0.2 mg demonstrated a numerical reduction for the primary endpoint of least squares mean change from baseline in adapted Mayo Score at Week 12 that did not meet statistical significance. …

Why Protagonist Therapeutics Shares Are Crashing Today

Protagonist Therapeutics Inc (NASDAQ:PTGX) announced topline results from the Phase 2 IDEAL study of PN-943 in moderate-to-severe ulcerative colitis (UC) patients. 159 patients with moderate-to-severe active UC were randomized to either twice daily (BID) with 450 mg or 150 mg PN-943, or placebo, for 12 weeks. While the 450 mg BID dose did…

The Daily Biotech Pulse: Protagonist's Ulcerative Colitis Study Disappoints, Gilead's Remdesivir Approved For Pediatric COVID-19 Patients, FDA Gives Nod To Gamida's Cell Therapy Trial, Fast Track Tag For Vascular Biogenics Ovarian Cancer Gene Therapy

Here's a roundup of top developments in the biotech space over the last 24 hours:

Teen who was 'too self-conscious' about symptoms diagnosed with chronic illness

Megan McNeil was suffering from extreme fatigue, weight loss and visiting the toilet 15-20 times an hour before being diagnosed with Ulcerative Colitis, with the now 21-year-old opening up about her journey

inkl

Read news from The Economist, FT, and more,
with one subscription

Woman diagnosed with chronic illness after years of embarrassment about symptoms

Woman diagnosed with chronic illness after years of embarrassment about symptoms

Megan McNeil, 21, was diagnosed with Ulcerative Colitis after she experienced symptoms such as passing blood when going to the bathroom

Protagonist Therapeutics Topline Data from Phase 2 IDEAL Study of PN-943 (450 mg BID) Miss Primary Endpoint

Protagonist Therapeutics (NASDAQ: PTGX) announced top-line results from the Phase 2 IDEAL clinical study evaluating PN-943 in patients with moderate-to-severe ulcerative colitis (UC).

Applied Molecular's AMT-101 Shows Favorable Clinical Activity, Safety Profile In Inflammatory Bowel Disease

Applied Molecular Transport Inc (NASDAQ:AMTI) announced Phase 2 topline results from the FILLMORE monotherapy trial for AMT-101 in chronic pouchitis. Pouchitis is inflammation in the lining of a pouch created during surgery to treat ulcerative colitis or certain other diseases. The trial demonstrated that 36.4% (8/22) of patients achieved stool frequency response. Rapid…

Gossamer Bio Pulls Plug On Mid-Stage Ulcerative Colitis Program

Gossamer Bio Pulls Plug On Mid-Stage Ulcerative Colitis Program

Gossamer Bio Inc (NASDAQ:GOSS) shares are falling after announcing topline results from its Phase 2 SHIFT-UC Study trial of GB004 in patients with mild-to-moderate active ulcerative colitis (UC). Neither GB004 treatment arm met the primary or secondary endpoints at week 12. Gossamer will terminate the ongoing treat-through and open-label extension portions of the…

Young woman diagnosed with chronic illness after feeling embarrassed about symptoms

Young woman diagnosed with chronic illness after feeling embarrassed about symptoms

Megan McNeil was diagnosed with Ulcerative Colitis after she experienced symptoms such as passing blood when going to the bathroom

1 2 3

Organisations

Glasgow Royal Infirmary

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

Ulcerative Colitis

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play